Characteristics associated with self-reported medication adherence in persons with psychosis referred to psychosocial rehabilitation centers.
Functional outcome
Medication adherence
Psychosocial rehabilitation
Quality of life
Self-stigma
Journal
European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
22
06
2020
accepted:
27
10
2020
pubmed:
11
11
2020
medline:
19
2
2022
entrez:
10
11
2020
Statut:
ppublish
Résumé
The aim of the present study was to explore the characteristics of psychotropic treatment and of psychosocial functioning associated with self-reported medication adherence in persons with psychosis engaged in rehabilitation. The study was performed in the REHABase cohort including persons referred to a French network of psychosocial rehabilitation centers. Treatment adherence was assessed using the Medication Adherence Rating Scale (MARS). The associations between MARS score (categorized as "low" < 7 vs. "high" ≥ 7) and functioning or psychotropic treatment characteristics were explored using multivariate analyses in 326 participants with schizophrenia spectrum disorders. Regarding psychotropic treatment, high anticholinergic load was the only characteristic associated with poor medication adherence (adjusted OR, aOR 1.98, 95% CI 1.07-3.66). Regarding functioning measures, participants with poor medication adherence were more likely to present with lower stage of recovery (aOR 2.38, 95% CI 1.31-4.32), poor quality of life (aOR 2.17, 95% CI 1.27-3.71), mental well-being (aOR 1.68, 95% CI 1.03-2.72) and self-esteem (aOR 1.74, 95% CI 1.05-2.87), and higher internalized stigma (aOR 1.88, 95% CI 1.09-3.23). Self-reported poor medication adherence is a marker of poor functioning in persons with psychosis. The MARS is a quick and simple measure of adherence that may be helpful in clinical and rehabilitation settings to identify persons with specific rehabilitation needs.
Identifiants
pubmed: 33169212
doi: 10.1007/s00406-020-01207-x
pii: 10.1007/s00406-020-01207-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1415-1424Informations de copyright
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Law H, Morrison AP (2014) Recovery in psychosis: a Delphi study with experts by experience. Schizophr Bull 40:1347–1355. https://doi.org/10.1093/schbul/sbu047
doi: 10.1093/schbul/sbu047
pubmed: 24727194
pmcid: 4193718
Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA (2009) Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull 35:336–346. https://doi.org/10.1093/schbul/sbn067
doi: 10.1093/schbul/sbn067
pubmed: 18586692
Leucht S, Heres S (2006) Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67(Suppl 5):3–8
pubmed: 16822090
Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F, van Os J (2000) Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand 102:203–210. https://doi.org/10.1034/j.1600-0447.2000.102003203.x
doi: 10.1034/j.1600-0447.2000.102003203.x
pubmed: 11008856
Goff DC, Hill M, Freudenreich O (2010) Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 71(Suppl 2):20–26. https://doi.org/10.4088/JCP.9096su1cc.04
doi: 10.4088/JCP.9096su1cc.04
pubmed: 21190649
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063–2071. https://doi.org/10.1016/S0140-6736(12)60239-6
doi: 10.1016/S0140-6736(12)60239-6
pubmed: 22560607
Velligan DI, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, Miller AL (2006) Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 32:724–742. https://doi.org/10.1093/schbul/sbj075
doi: 10.1093/schbul/sbj075
pubmed: 16707778
pmcid: 2632258
Velligan DI, Maples NJ, Pokorny JJ, Wright C (2020) Assessment of adherence to oral antipsychotic medications: what has changed over the past decade? Schizophr Res 215:17–24. https://doi.org/10.1016/j.schres.2019.11.022
doi: 10.1016/j.schres.2019.11.022
pubmed: 31767511
Garcia S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, Zorrilla I, Lopez P, Vieta E, Gonzalez-Pinto A (2016) Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 36:355–371. https://doi.org/10.1097/JCP.0000000000000523
doi: 10.1097/JCP.0000000000000523
pubmed: 27307187
pmcid: 4932152
Cramer JA, Rosenheck R (1998) Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196–201. https://doi.org/10.1176/ps.49.2.196
doi: 10.1176/ps.49.2.196
pubmed: 9575004
Kane JM, Kishimoto T, Correll CU (2013) Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 12:216–226. https://doi.org/10.1002/wps.20060
doi: 10.1002/wps.20060
pubmed: 24096780
pmcid: 3799245
Barbui C, Kikkert M, Mazzi MA, Becker T, Bindman J, Schene A, Nose M, Helm H, Thornicroft G, Tansella M (2009) Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence. Psychopathology 42:311–317. https://doi.org/10.1159/000232973
doi: 10.1159/000232973
pubmed: 19672133
Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, Aikens JE, Hunter CM, Velligan DI, Huntley K, Ogedegbe G, Rand CS, Schron E, Nilsen WJ (2015) Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med 5:470–482. https://doi.org/10.1007/s13142-015-0315-2
doi: 10.1007/s13142-015-0315-2
pubmed: 26622919
pmcid: 4656225
Byerly MJ, Thompson A, Carmody T, Bugno R, Erwin T, Kashner M, Rush AJ (2007) Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv 58:844–847. https://doi.org/10.1176/ps.2007.58.6.844
doi: 10.1176/ps.2007.58.6.844
pubmed: 17535946
Jonsdottir H, Opjordsmoen S, Birkenaes AB, Engh JA, Ringen PA, Vaskinn A, Aamo TO, Friis S, Andreassen OA (2010) Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level. J Clin Psychopharmacol 30:169–175. https://doi.org/10.1097/JCP.0b013e3181d2191e
doi: 10.1097/JCP.0b013e3181d2191e
pubmed: 20520290
Fialko L, Garety PA, Kuipers E, Dunn G, Bebbington PE, Fowler D, Freeman D (2008) A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophr Res 100:53–59. https://doi.org/10.1016/j.schres.2007.10.029
doi: 10.1016/j.schres.2007.10.029
pubmed: 18083007
Lien YJ, Chang HA, Kao YC, Tzeng NS, Lu CW, Loh CH (2018a) The impact of cognitive insight, self-stigma, and medication compliance on the quality of life in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 268:27–38. https://doi.org/10.1007/s00406-017-0829-3
doi: 10.1007/s00406-017-0829-3
pubmed: 28756468
Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC (2004) Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 65:1372–1376. https://doi.org/10.4088/jcp.v65n1012
doi: 10.4088/jcp.v65n1012
pubmed: 15491241
Puschner B, Angermeyer MC, Leese M, Thornicroft G, Schene A, Kikkert M, Burti L, Tansella M, Becker T (2009) Course of adherence to medication and quality of life in people with schizophrenia. Psychiatry Res 165:224–233. https://doi.org/10.1016/j.psychres.2007.10.011
doi: 10.1016/j.psychres.2007.10.011
pubmed: 19155070
Franck N, Bon L, Dekerle M, Plasse J, Massoubre C, Pommier R, Legros-Lafarge E, Jaafari N, Guillard-Bouhet N, Quiles C, Couhet G, Verdoux H, Gouache B, Martin B, Cervello S, Demily C, Dubreucq J (2019) Satisfaction and needs in serious mental illness and autism spectrum disorder: the REHABase psychosocial rehabilitation project. Psychiatr Serv 70:316–323. https://doi.org/10.1176/appi.ps.201800420
doi: 10.1176/appi.ps.201800420
pubmed: 30691384
Verdoux H, Quiles C, Cervello S, Dubreucq J, Bon L, Massoubre C, Pommier R, Legros-Lafarge E, Jaafari N, Guillard-Bouhet N, Chereau-Boudet I, Couhet G, Plasse J, Franck N (2019) Functioning and cognitive characteristics of clozapine users referred to psychosocial rehabilitation centers: a REHABase cohort study. Psychiatry Res 281:112543. https://doi.org/10.1016/j.psychres.2019.112543
doi: 10.1016/j.psychres.2019.112543
pubmed: 31493715
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. Arlington
Thompson K, Kulkarni J, Sergejew AA (2000) Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 42:241–247
doi: 10.1016/S0920-9964(99)00130-9
Misdrahi D, Verdoux H, Llorca PM, Bayle FJ (2004) Therapeutic adherence and schizophrenia: the interest of the validation of the French translation of Medication Adherence Rating Scale (MARS). Encephale 30:409–410
pubmed: 15597462
Fond G, Boyer L, Boucekine M, Aden LA, Schurhoff F, Tessier A, Andrianarisoa M, Berna F, Brunel L, Capdevielle D, Chereau I, Mallet J, Denizot H, Dorey JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Rey R, Richieri R, Passerieux C, Schandrin A, Urbach M, Vidailhet P, Llorca PM, Misdrahi D, group F-S (2017) Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset. Schizophr Res 182:84–89. https://doi.org/10.1016/j.schres.2016.10.023
doi: 10.1016/j.schres.2016.10.023
pubmed: 27789187
Misdrahi D, Tessier A, Swendsen J, Berna F, Brunel L, Capdevielle D, Chereau I, Danion JM, De Pradier M, Dorey JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Rey R, Richieri R, Passerieux C, Schandrin A, Schurhoff F, Tronche AM, Urbach M, Llorca PM, Fond G (2016) Determination of adherence profiles in schizophrenia using self-reported adherence: results from the FACE-SZ dataset. J Clin Psychiatry 77:e1130–e1136. https://doi.org/10.4088/JCP.15m10115
doi: 10.4088/JCP.15m10115
pubmed: 27780318
Verdoux H, Quiles C, Bon L, Chereau-Boudet I, Dubreucq J, Fiegi L, Guillard-Bouhet N, Massoubre C, Plasse J, Franck N (2020) Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers. Psychol Med. https://doi.org/10.1017/S0033291720001403
doi: 10.1017/S0033291720001403
pubmed: 33196405
Salahudeen MS, Duffull SB, Nishtala PS (2015) Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr 15:31. https://doi.org/10.1186/s12877-015-0029-9
doi: 10.1186/s12877-015-0029-9
pubmed: 25879993
pmcid: 4377853
Duran CE, Azermai M, Vander Stichele RH (2013) Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol 69:1485–1496. https://doi.org/10.1007/s00228-013-1499-3
doi: 10.1007/s00228-013-1499-3
pubmed: 23529548
Guy W (1976) ECDEU assessment manual for psychopharmacology. Department of Health, Education, and Welfare, Rockville
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. Text Revision (DSM-IV-TR). Washington, DC
Andresen R, Caputi P, Oades L (2006) Stages of recovery instrument: development of a measure of recovery from serious mental illness. Aust N Z J Psychiatry 40:972–980. https://doi.org/10.1080/j.1440-1614.2006.01921.x
doi: 10.1080/j.1440-1614.2006.01921.x
pubmed: 17054565
Boyer L, Simeoni MC, Loundou A, D’Amato T, Reine G, Lancon C, Auquier P (2010) The development of the S-QoL 18: a shortened quality of life questionnaire for patients with schizophrenia. Schizophr Res 121:241–250. https://doi.org/10.1016/j.schres.2010.05.019
doi: 10.1016/j.schres.2010.05.019
pubmed: 20541912
pmcid: 20541912
Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, Parkinson J, Secker J, Stewart-Brown S (2007) The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes 5:63. https://doi.org/10.1186/1477-7525-5-63
doi: 10.1186/1477-7525-5-63
pubmed: 18042300
pmcid: 2222612
Trousselard M, Steiler D, Dutheil F, Claverie D, Canini F, Fenouillet F, Naughton G, Stewart-Brown S, Franck N (2016) Validation of the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) in French psychiatric and general populations. Psychiatry Res 245:282–290. https://doi.org/10.1016/j.psychres.2016.08.050
doi: 10.1016/j.psychres.2016.08.050
pubmed: 27565700
Ritsher JB, Otilingam PG, Grajales M (2003) Internalized stigma of mental illness: psychometric properties of a new measure. Psychiatry Res 121:31–49
doi: 10.1016/j.psychres.2003.08.008
Brohan E, Gauci D, Sartorius N, Thornicroft G, Group GA-ES (2011) Self-stigma, empowerment and perceived discrimination among people with bipolar disorder or depression in 13 European countries: the GAMIAN-Europe study. J Affect Disord 129:56–63. https://doi.org/10.1016/j.jad.2010.09.001
doi: 10.1016/j.jad.2010.09.001
pubmed: 20888050
Rosenberg M (1965) Society and the adolescent self-image. Princeton University Press, Princeton
Vallieres E, Vallerand AL (1990) Traduction et validation canadienne française de l’échelle de l’estime de soi de Rosenberg. Int J Psychol 25:305–316
doi: 10.1080/00207599008247865
Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M (1994) A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand 89:62–67
doi: 10.1111/j.1600-0447.1994.tb01487.x
Jonsdottir H, Opjordsmoen S, Birkenaes AB, Simonsen C, Engh JA, Ringen PA, Vaskinn A, Friis S, Sundet K, Andreassen OA (2013) Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand 127:23–33. https://doi.org/10.1111/j.1600-0447.2012.01911.x
doi: 10.1111/j.1600-0447.2012.01911.x
pubmed: 22900964
Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP, Expert Consensus Panel on Adherence Problems in S, Persistent Mental I (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70(Suppl 4):1–46 (quiz 47–48)
pubmed: 19686636
Nielsen J, Munk-Jorgensen P, Skadhede S, Correll CU (2011) Determinants of poor dental care in patients with schizophrenia: a historical, prospective database study. J Clin Psychiatry 72:140–143. https://doi.org/10.4088/JCP.09m05318yel
doi: 10.4088/JCP.09m05318yel
pubmed: 20584518
Cicala G, Barbieri MA, Spina E, de Leon J (2019) A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. Exp Rev Clin Pharmacol 12:219–234. https://doi.org/10.1080/17512433.2019.1577134
doi: 10.1080/17512433.2019.1577134
Cohen D (2017) Clozapine and gastrointestinal hypomotility. CNS Drugs 31:1083–1091. https://doi.org/10.1007/s40263-017-0481-5
doi: 10.1007/s40263-017-0481-5
pubmed: 29230675
Verdoux H, Pambrun E, Tournier M, Cortaredona S, Verger P (2019) Multi-trajectories of antidepressant and antipsychotic use: a 11-year naturalistic study in a community-based sample. Acta Psychiatr Scand 139:536–547. https://doi.org/10.1111/acps.13020
doi: 10.1111/acps.13020
pubmed: 30844084
Tiihonen J, Mittendorfer-Rutz E, Torniainen M, Alexanderson K, Tanskanen A (2016) Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 173:600–606. https://doi.org/10.1176/appi.ajp.2015.15050618
doi: 10.1176/appi.ajp.2015.15050618
pubmed: 26651392
Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H (2020) Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta-analysis. CNS Drugs 34:579–598. https://doi.org/10.1007/s40263-020-00713-9
doi: 10.1007/s40263-020-00713-9
pubmed: 32219681
Sendt KV, Tracy DK, Bhattacharyya S (2015) A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res 225:14–30. https://doi.org/10.1016/j.psychres.2014.11.002
doi: 10.1016/j.psychres.2014.11.002
pubmed: 25466227
Acosta FJ, Hernandez JL, Pereira J, Herrera J, Rodriguez CJ (2012) Medication adherence in schizophrenia. World J Psychiatry 2:74–82. https://doi.org/10.5498/wjp.v2.i5.74
doi: 10.5498/wjp.v2.i5.74
pubmed: 24175171
pmcid: 3782179
Moritz S, Berna F, Jaeger S, Westermann S, Nagel M (2017) The customer is always right? Subjective target symptoms and treatment preferences in patients with psychosis. Eur Arch Psychiatry Clin Neurosci 267:335–339. https://doi.org/10.1007/s00406-016-0694-5
doi: 10.1007/s00406-016-0694-5
pubmed: 27194554
Uhlmann C, Kaehler J, Harris MS, Unser J, Arolt V, Lencer R (2014) Negative impact of self-stigmatization on attitude toward medication adherence in patients with psychosis. J Psychiatr Pract 20:405–410. https://doi.org/10.1097/01.pra.0000454787.75106.ae
doi: 10.1097/01.pra.0000454787.75106.ae
pubmed: 25226204
Feldhaus T, Falke S, von Gruchalla L, Maisch B, Uhlmann C, Bock E, Lencer R (2018) The impact of self-stigmatization on medication attitude in schizophrenia patients. Psychiatry Res 261:391–399. https://doi.org/10.1016/j.psychres.2018.01.012
doi: 10.1016/j.psychres.2018.01.012
pubmed: 29353769
Lien YJ, Chang HA, Kao YC, Tzeng NS, Lu CW, Loh CH (2018b) Insight, self-stigma and psychosocial outcomes in Schizophrenia: a structural equation modelling approach. Epidemiol Psychiatr Sci 27:176–185. https://doi.org/10.1017/S2045796016000950
doi: 10.1017/S2045796016000950
pubmed: 27974084
Caqueo-Urizar A, Urzua A, Habib J, Loundou A, Boucekine M, Boyer L, Fond G (2019) Relationships between social stigma, stigma experience and self-stigma and impaired quality of life in schizophrenia across three Latin-American countries. Eur Arch Psychiatry Clin Neurosci. https://doi.org/10.1007/s00406-019-01035-8
doi: 10.1007/s00406-019-01035-8
pubmed: 31240445
Drake RJ, Nordentoft M, Haddock G, Arango C, Fleischhacker WW, Glenthoj B, Leboyer M, Leucht S, Leweke M, McGuire P, Meyer-Lindenberg A, Rujescu D, Sommer IE, Kahn RS, Lewis SW (2015) Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. Schizophr Bull 41:584–596. https://doi.org/10.1093/schbul/sbv015
doi: 10.1093/schbul/sbv015
pubmed: 25750247
pmcid: 4393703
Dubreucq J, Plasse J, Gabayet F, Faraldo M, Blanc O, Chereau I, Cervello S, Couhet G, Demily C, Guillard-Bouhet N, Gouache B, Jaafari N, Legrand G, Legros-Lafarge E, Pommier R, Quiles C, Straub D, Verdoux H, Vignaga F, Massoubre C, Network RE, Franck N (2020) Self-stigma in serious mental illness and autism spectrum disorder: results from the REHABase national psychiatric rehabilitation cohort. Eur Psychiatry 63:e13. https://doi.org/10.1192/j.eurpsy.2019.12
doi: 10.1192/j.eurpsy.2019.12
pubmed: 32093806
pmcid: 7315867
Gaebel W, Zaske H, Hesse K, Klingberg S, Ohmann C, Grebe J, Kolbe H, Icks A, Schneider F, Backes V, Wolff-Menzler C, Guse B, Gallinat J, Bock T, Jockers-Scherubl MC, Kruger T, Jessen F, Bechdolf A, Kircher T, Konrad C, Falkai P, Schaub A, Rudolph M, Kollner V, Schmid-Ott G, Linden M, Lieberei B, Stuhlinger M, Sommerfeld S, Schumacher A, Krenge S, Gereke S, Monter N, Navarro-Urena A, Frosch G, Kuhlbusch FJ, Cleveland H, Riesbeck M (2019) Promoting stigma coping and empowerment in patients with schizophrenia and depression: results of a cluster-RCT. Eur Arch Psychiatry Clin Neurosci. https://doi.org/10.1007/s00406-019-01064-3
doi: 10.1007/s00406-019-01064-3
pubmed: 31654119